Oncotelic Therapeutics AI Stock Analysis
Want to see OTLC full AI Analyst Report?
Oncotelic Therapeutics (OTLC) AI Stock Analysis
Oncotelic Therapeutics
(Other OTC:OTLC)
The overall score is constrained by weak technicals and poor core financial performance, as the company remains pre-revenue with significant operating losses. The strong balance sheet provides a safety net, and recent AI platform presentations offer a potential long-term catalyst, but near-term dilution risk from convertible financing and a sustained stock downtrend weigh heavily on the outlook.
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 386.08K
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 0.11
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 41
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound desig...
Oncotelic Therapeutics Financial Statement Overview
Summary
The balance sheet is robust with a debt-to-equity ratio of 0.06, providing a strong financial cushion. However, core operations are deeply unprofitable with an operating loss and negative cash flows, typical of a pre-revenue biotech. The massive net income is a non-recurring event and does not reflect operational health.
Income Statement
25NegativeBalance Sheet
85Very PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.00K | 0 | 0 | 70.00K | 0 | 0 |
| Gross Profit | 250.00K | 0 | 0 | 70.00K | -12.84K | -61.51K |
| EBITDA | 360.34M | 361.46M | -3.80M | -6.86M | -5.60M | -9.06M |
| Net Income | 247.50M | 249.28M | -4.52B | -7.90M | 17.82M | -11.39M |
Balance Sheet | ||||||
| Total Assets | 394.75M | 393.09M | 26.68M | 30.01M | 36.12M | 23.61M |
| Cash, Cash Equivalents and Short-Term Investments | 186.01K | 88.86K | 86.13K | 170.41K | 241.45K | 568.77K |
| Total Debt | 13.89M | 13.91M | 13.09M | 12.57M | 11.26M | 8.99M |
| Total Liabilities | 131.31M | 131.36M | 19.20M | 18.40M | 16.92M | 15.45M |
| Stockholders Equity | 264.56M | 262.76M | 8.25M | 12.13M | 19.41M | 7.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.52M | -1.38M | -740.27K | -1.32M | -1.45M | -4.43M |
| Operating Cash Flow | -1.52M | -1.38M | -740.27K | -1.32M | -1.45M | -4.43M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.39M | 656.00K | 1.25M | 1.13M | 4.53M |
Oncotelic Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 34.70 is Neutral, neither overbought nor oversold. The STOCH value of 10.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 38 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskOncotelic Therapeutics Peers Comparison
Overall Rating
GRCE49Neutral- OTLC48Neutral
ELUT47Neutral
LTRN44Neutral
MAIA44Neutral
CALC42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GRCE | 49Neutral | $39.02M | -1.40 | -35.78% | ― | ― | -110.40% |
| OTLC | 48Neutral | $6.08M | 0.02 | 123.80% | ― | ― | ― |
| ELUT | 47Neutral | $40.75M | 0.71 | 267.71% | ― | -52.81% | 7.54% |
| LTRN | 44Neutral | $7.18M | -0.29 | -456.35% | ― | ― | 9.68% |
| MAIA | 44Neutral | $63.60M | -2.11 | -153.44% | ― | ― | 35.05% |
| CALC | 42Neutral | $8.55M | -0.28 | -3029.57% | ― | ― | 45.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics Inc | 0.01 | -0.07 | -84.71% | |
| GRCE | Grace Therapeutics, Inc. | 1.81 | -1.25 | -40.85% | |
| LTRN | Lantern Pharma, Inc. | 0.46 | -2.92 | -86.39% | |
| CALC | Calcimedica, Inc. | 1.22 | -13.78 | -91.87% | |
| ELUT | Elutia Inc. | 0.88 | 0.13 | 17.85% | |
| MAIA | MAIA Biotechnology, Inc. | 1.01 | -0.03 | -2.88% |
Oncotelic Therapeutics Corporate Events
Oncotelic showcases AI-driven oncology discovery framework
PositiveOn October 22, 2026, Oncotelic Therapeutics Chief Business Officer Saran Saund presented the company’s Partitioned Literature Aggregation framework at the 22nd Drug Discovery Strategic Summit in Millbrae, California. The talk detailed how partitionin...
Oncotelic highlights PDAOAI platform and BIO REBOOT initiative
PositiveOn October 7 and 8, 2026, Oncotelic Therapeutics representatives presented new technical details of their PDAOAI data-analytics platform and hepatocellular carcinoma research at the Drug Discovery 2026 conference in Burlingame, California. The platfo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026